Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆

ESMO Guidelines Committee

doi:10.1016/j.annonc.2025.07.014

Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up^☆

ESMO Guidelines Committee

Department of Translational Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

This ESMO CPG provides key recommendations and algorithms for managing DLBCL, FL, HL, MCL, MZL, PCNSL and PTCL. •It covers epidemiology, diagnosis, staging, risk assessment, treatment of primary and refractory disease and follow-up. •Treatment algorithms for each lymphoma type are provided. •The author group encompasses a multidisciplinary group of experts from different institutions and countries in Europe. •Recommendations are based on available scientific data and the authors’ collective expert opinion.

Original language	English
Pages (from-to)	1263-1284
Number of pages	22
Journal	Annals of Oncology
Volume	36
Issue number	11
DOIs	https://doi.org/10.1016/j.annonc.2025.07.014
Publication status	Published - Nov 2025

Keywords

diagnosis
guideline
immunotherapy
lymphoma
treatment

Access to Document

10.1016/j.annonc.2025.07.014

Cite this

@article{aac4dc9f529240d29c94a2fcc6c35113,

title = "Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆",

abstract = "This ESMO CPG provides key recommendations and algorithms for managing DLBCL, FL, HL, MCL, MZL, PCNSL and PTCL. •It covers epidemiology, diagnosis, staging, risk assessment, treatment of primary and refractory disease and follow-up. •Treatment algorithms for each lymphoma type are provided. •The author group encompasses a multidisciplinary group of experts from different institutions and countries in Europe. •Recommendations are based on available scientific data and the authors{\textquoteright} collective expert opinion.",

keywords = "diagnosis, guideline, immunotherapy, lymphoma, treatment",

author = "\{ESMO Guidelines Committee\} and Eyre, \{T. A.\} and K. Cwynarski and F. d{\textquoteright}Amore and \{de Leval\}, L. and M. Dreyling and Eichenauer, \{D. A.\} and Ferreri, \{A. J.M.\} and E. Gin{\'e} and Kersten, \{M. J.\} and M. Ladetto and L. Specht and C. Thieblemont and J. Walewski and E. Zucca and M. Jerkeman",

note = "Publisher Copyright: {\textcopyright} 2025 European Society for Medical Oncology. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.",

year = "2025",

month = nov,

doi = "10.1016/j.annonc.2025.07.014",

language = "English",

volume = "36",

pages = "1263--1284",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "11",

}

TY - JOUR

T1 - Lymphomas

T2 - ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆

AU - ESMO Guidelines Committee

AU - Eyre, T. A.

AU - Cwynarski, K.

AU - d’Amore, F.

AU - de Leval, L.

AU - Dreyling, M.

AU - Eichenauer, D. A.

AU - Ferreri, A. J.M.

AU - Giné, E.

AU - Kersten, M. J.

AU - Ladetto, M.

AU - Specht, L.

AU - Thieblemont, C.

AU - Walewski, J.

AU - Zucca, E.

AU - Jerkeman, M.

N1 - Publisher Copyright: © 2025 European Society for Medical Oncology. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

PY - 2025/11

Y1 - 2025/11

N2 - This ESMO CPG provides key recommendations and algorithms for managing DLBCL, FL, HL, MCL, MZL, PCNSL and PTCL. •It covers epidemiology, diagnosis, staging, risk assessment, treatment of primary and refractory disease and follow-up. •Treatment algorithms for each lymphoma type are provided. •The author group encompasses a multidisciplinary group of experts from different institutions and countries in Europe. •Recommendations are based on available scientific data and the authors’ collective expert opinion.

AB - This ESMO CPG provides key recommendations and algorithms for managing DLBCL, FL, HL, MCL, MZL, PCNSL and PTCL. •It covers epidemiology, diagnosis, staging, risk assessment, treatment of primary and refractory disease and follow-up. •Treatment algorithms for each lymphoma type are provided. •The author group encompasses a multidisciplinary group of experts from different institutions and countries in Europe. •Recommendations are based on available scientific data and the authors’ collective expert opinion.

KW - diagnosis

KW - guideline

KW - immunotherapy

KW - lymphoma

KW - treatment

UR - https://www.scopus.com/pages/publications/105018023772

U2 - 10.1016/j.annonc.2025.07.014

DO - 10.1016/j.annonc.2025.07.014

M3 - Article

SN - 0923-7534

VL - 36

SP - 1263

EP - 1284

JO - Annals of Oncology

JF - Annals of Oncology

IS - 11

ER -

Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up^☆

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this